Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multi-Center, Phase II Clinical Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Relapsed or Refractory Primary Light-Chain Amyloidosis

Next Previous
Trial Profile

An Open-Label, Multi-Center, Phase II Clinical Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Relapsed or Refractory Primary Light-Chain Amyloidosis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CM 336 (Primary)
  • Indications Amyloid light-chain amyloidosis
  • Focus Therapeutic Use
  • Sponsors KeyMed Biosciences

Most Recent Events

  • 26 Jun 2025 Status changed from planning to recruiting.
  • 20 Jun 2025 New trial record
  • 15 Jun 2025 According to a Keymed Biosciences media release, the Center for Drug Evaluation of the National Medical Products Administration has approved phase II clinical study of CM336 for the treatment of primary light-chain amyloidosis.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top